Background {#Sec1}
==========

A new pleural effusion may be caused by a wide range of conditions. The British Thoracic Society produced guidelines in 2010 recommending a systematic approach to achieve a diagnosis, aiming to streamline investigations and interventions \[[@CR1]\]. Since then, the evidence base for managing malignant and infective effusions has developed through a series of clinical trials. In comparison, research on benign non-infective pleural effusions has been more limited \[[@CR2]\]. A number of these are caused by connective tissue diseases (CTD).

Pleural effusions from CTD are caused by increased capillary permeability, as extravascular fluid moves from the lung's interstitium, across the mesothelium into the pleural space \[[@CR3]\]. This may be due to a number of reasons \[[@CR4]\], such as a pleural infiltrative process. In addition, circulating immune complexes that localise to the pleura, can activate the complement system causing endothelial injury. Enzyme and free radical release from white blood cells also accentuate the inflammatory process.

CTD-related pleural effusions are rare and challenging to diagnose. The most common CTDs to affect the pleura are rheumatoid arthritis and systemic lupus erythematosus (SLE) \[[@CR1]\]. A prospective observational cohort study over 7 years at a specialist pleural unit identified 356 nonmalignant pleural effusions. 9.8% of these were given a diagnosis of inflammatory pleuritis, and 7.6% attributed to other diagnoses (including chylothorax, rheumatic causes, trauma, and drug-induced causes) \[[@CR5]\].

The same unit described the value of a pleural specialist team to improve the efficacy and efficiency of managing patients with pleural disease \[[@CR6]\]. In most pleural teams, the medical specialties involved are commonly: respiratory, oncology and palliative care. However, the pleural team in our centre works closely with the lung inflammation service, with expertise in rheumatology, interstitial lung disease and respiratory failure. This study aims to review the multidisciplinary approach to CTD-related pleural effusions at a tertiary centre. To our knowledge, there is no published evidence describing a multidisciplinary approach to CTD-related pleural effusions.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

This study is a retrospective evaluation of cases. We reviewed electronic hospital records, imaging, blood tests, pleural fluid analysis and pleural biopsy analysis. Data were collected relating to CTD diagnosis, pleural and surgical interventions, and CTD specific systemic therapy.

As a retrospective service evaluation, written patient informed consent and regional ethics approval was not required.

Participants {#Sec4}
------------

All patients diagnosed with CTD-related pleural effusions at St Thomas' Hospital, London were included. We included patients referred to pleural clinic between November 2012 and 2016. These patients are usually referred by the general medical or rheumatology teams for a specialist pleural opinion when the etiology of the pleural effusion is unclear, or where there is an acute clinical concern. We excluded patients with a CTD attending pleural clinic with a pleural effusion due to other (non-CTD related) etiologies.

Interventions {#Sec5}
-------------

Pleural aspirations, drains, biopsies and medical thoracoscopies were performed in the pleural clinic at St Thomas' Hospital in accordance with national guidelines \[[@CR7], [@CR8]\]. Out of hours, aspirations and drains were performed by the radiology department.

Assessments {#Sec6}
-----------

Statistical analysis was carried out using Microsoft Excel. Descriptive statistics were used to evaluable the service, and to summarise the clinical characteristics of the subjects.

Results {#Sec7}
=======

Eleven patients (ages 23--77) were identified with CTD related pleural disease (Table [1](#Tab1){ref-type="table"}). They were seen by the lung inflammation service, who performed an expert clinical assessment and targeted investigations, usually after review by the pleural team. 9 (82%) patients were given a new CTD diagnosis, with pleural disease as the first manifestation. The range of conditions were: rheumatoid arthritis \[3\], IgG4-related disease \[2\], adult Still's disease \[2\], vasculitis \[1\], SLE \[1\], drug (carbamazepine)-induced lupus \[1\], and Behcet's \[1\]. Table 1Patient demographicsCharacteristic*n* (%)Gender (*n* = 11) Male8 (73) Female3 (27)Age range23--77Median age50CTD diagnosis Rheumatoid arthritis3 (27) IgG4-related disease2 (18) Adult Still's disease2 (18) Vasculitis1 (9) SLE1 (9) Drug-induced lupus1 (9) Behcet's1 (9)

The pleural team review took place 1 day (median) after referral. 73% of diagnoses (8 patients) were achieved with local anaesthetic pleural interventions (a combination of: aspiration, drain, or percutaneous biopsy). This included 1 patient who required no pleural intervention. 1 required medical thoracoscopy, and 2 underwent thoracic surgery (Table [2](#Tab2){ref-type="table"}). The patient who underwent a medical thoracoscopy (for pleural thickening) after an aspiration, had a final diagnosis of a rheumatoid arthritis associated pleural effusion. One patient who underwent thoracic surgery was referred directly to the surgical team, subsequently requiring a pericardiectomy for a diagnosis of IgG4-related disease. Another patient underwent VATS to rule out a pleural malignancy, before commencing treatment for a pleural effusion related to drug-induced lupus. Table 2Pleural/surgical interventionsPleural intervention*n* (%)None1 (9)Pleural aspiration only3 (27)Chest drain only2 (18)Pleural aspiration and chest drain1 (9)Pleural aspiration and biopsy1 (9)Pleural aspiration and biopsy, drain and VATS1 (9)Pleural aspiration and medical thoracoscopy1 (9)VATS, thoracotomy, pericardiectomy1 (9)

Table [3](#Tab3){ref-type="table"} illustrates how diagnoses were made by integrating and analysing all available evidence, to include clinical assessment, imaging, and autoimmune serology. No diagnosis was achieved by pleural cytology or histology analysis alone. The pleural fluid pH was not measured for these patients (although it is available at our centre), as pleural infection was low on the list of differentials. Table 3Key clinical information of patientsConnective tissue disease diagnosisPresenting symptoms / Autoimmune serologyEvidence for diagnosis\*Pleural fluid glucose (mmol/L)Pleural fluid LDH (IU/L)Pleural fluid protein (g/L)Pleural microPleural fluid appearancePleural fluid cytologyHistologyCT chest findingsOutcomeRheumatoid arthritisPleuritic chest pain, dyspnoea, polyarthralgia, fatigue anti-CCP + veClinical assessment, autoimmune serology3.479455Fluid MCS/AFB negBiopsy AFB negTurbid yellow fluid2/3/16 Neutrophils, lymphocytes, macrophages, prominent eosinophils. Few reactive mesothelial cells.23/3/16 Mixed lymphoid cell population; plasma cells and eosinophils. Occasional mesothelial cells.Pleural biopsy: moderate acute and mild chronic inflammation, surface mesothelial denudation, macrophages and fibrin.Bilateral hilar lymphadenopathy. Left-sided pleural effusion and bibasal groundglass change with intralobular septal thickening demonstrated.Resolution of pleural effusions on CXR by week 7 on weaning prednisolone (after pulsed methylprednisolone)Rheumatoid arthritisFever, cough, fatigue, pleuritic chest pain, dyspnoea anti-CCP and RhF + vePrevious CTD diagnosis, clinical assessment, autoimmune serologyNoneNoneNonen/an/aNoneNonePericardial hyperattenuation, either in keeping with thickening and low-grade enhancement or a complex pericardial effusion. Shallow left pleural effusion.Resolution of pleural effusions 5 months after pleural review (one prior week of prednisolone)Rheumatoid arthritisCough, feveranti-CCP and RhF + vePrevious CTD diagnosis, clinical assessment, pleural fluid glucose, pleural biopsy0594755Fluid MCS/AFB negBiopsy AFB negTurbid yellow fluidLymphocytes and macrophages and scattered histiocytic multi-nucleate giant cellsPleural biopsy: fibrous tissue with a dense lymphoplasmacytic infiltrate. Suggestion of histiocyte palisading; possibility of rheumatoid nodule, but insufficient for definitive diagnosis.Moderate right pleural effusion. A calcified granuloma is noted in the right lower lobe. Minor right subpleural nodularity is seen. Emphysema.Pleural effusion stable 1 year after discharge from pleural clinic (during which 5 mg prednisolone daily started for joint pains)IgG4-related diseaseDyspnoea, cough, oedemaIgG4 2.71 (0.23--1.11 g/L)IgG1 11.3 (4.8--9.5 g/L)Pericardiectomy histology, autoimmune serologyNoneNoneNoneFluid MCS/AFB negBiopsy AFB/MCS negBloodstained fluidA few benign mesothelial cells(Pleural biopsy: mildly inflamed pleural tissue. Single non-necrotising granuloma.)Pericardial biopsy: dense keloid-like fibrosis. Foci of chronic inflammation and in these IgG4 plasma cells comprise a high population of IgG+ plasma cells.Right pleural effusion and ascites. Cervical and mediastinal lymphadenopathy.Pericardial calcification and thickening suggest previous pericardial effusion/pericarditis.Pleural effusion improved over 2 months (prednisolone started then weaned off onto methotrexate)IgG4-related diseaseDyspnoea, dizzinessIgG4 1.53 (0.23--1.11 g/L)IgG1 12.4 (4.8--9.5 g/L)Pericardiectomy histology, clinical assessment, autoimmune serologyNone276Fluid Scanty growth *Staphylococcus aureus*, AFB negSlightly cloudy yellow fluidMesothelial cells and mixed inflammatory cells (predominantly neutrophil polymorphs).Pericardial biopsy: Diffuse moderate to severe fibrosis associated with focal calcification and mild chronic inflammatory cell infiltrate. IgA shows non-specific patchy mild staining.Small bilateral pleural effusions. No pericardial effusion although some pericardial calcification is noted. Likely reactive mediastinal nodes.Left pleural effusion resolved and small right pleural effusion 1 year after pleural review (started on furosemide)Adult Still's diseaseFever, cough, dyspnoea, chest pain, myalgia, sore throat, rashClinical assessment, raised ferritin10.389433Fluid MCS/AFB negStraw coloured fluidAcute inflmmatory cells. A few reactive mesothelial cells, histiocytes and lymphocytes.NoneSmall bilateral pleural effusions with bibasal collapse/consolidation. Moderate pericardial effusion.Pleural effusions resolved after 1 month (weaning prednisolone and colchicine)Adult Still's diseasePleuritic chest pain, dyspnoea, fever, sore throat, arthralgiaClinical assessmentNoneNone34Fluid MCS/AFB negCloudy yellow fluidNumerous neutrophils (95%) with occasional macrophages and mesothelial cells.NoneSmall bilateral pleural effusions and a trace of pericardial fluid.Pleural effusions resolved after 2 months (weaning prednisolone and colchicine)VasculitisDyspnoea, weight loss, appetite lossP-ANCA, Anti-MPO 222 (0-10 U/ml)Clinical assessment, autoimmune serology, CT showing adrenal infarcts6.927948Fluid MCS/AFB negBloodstained fluidMixed lymphoid cell population along with neutrophil polymorphs, histiocytes and very occasional mesothelial cell.noneBilateral calcified pleural plaques. Right pleural thickening and effusion. Emphysema. Multiple solid subpleural and peri-fissural bilateral nodulesPleural effusion resolved after 5 months (4 month course of weaning prednisolone)SLEPleuritic chest pain, dyspnoeaAnti ds-DNA 415 (0-10 IU/ml), anti-Smith +vePrevious CTD diagnosis, clinical assessment5.230459Fluid MCS/AFB negCloudy light brown fluidMesothelial cells, macrophages, neutrophils and lymphocytes.noneNonePleural effusion resolved after 7 months (prednisolone weaned to maintenance)Drug-induced lupus (cabamazepine)Dyspnoea, rash, ulceration of hands and feetANA +ve, ENA RNP + ve, ENA SSA (Ro) + ve, ENA Sm + veANCA negClinical assessment, autoimmune serology6.522847Fluid MCS/AFB negBiopsy AFB/MCS negTurbid orange fluid16/11/12 Reactive mesothelial cells, polymorphs, lymphocytes and histiocytes.5/12/12 Numerous mesothelial cells, macrophages and a mixed population of lymphocytes.11/12/12 Histiocytes, a few lymphocytes and reactive mesothelial cells.18/12/12 Reactive mesothelial cells, lymphocytes and histiocytes.27/12/12 Histiocytes, lymphocytes, reactive mesothelial cells, neutrophils, plasma cells.13/1/13 Blood only.16/11/12 pleural biopsy: Single focus of large cells at the edge of one fragment, most likely reactive mesothelial cells. Nuclei are pleomorphic, irregular nuclear membranes and nuclear chromatin clearing.13/1/13 pleural biopsy: Pleura markedly oedematous; granulation tissue at the surface, scattered foci of chronic inflammatory cells.Left pleural effusion with minimal nodularity and mild volume loss in the left hemithorax. Shallow pericardial effusion. Widespread mild lymphadenopathy.Pleural effusion resolved after 9 months (prednisolone weaned to maintenance)Behcet'sChest tightnessClinical assessment4.838044Fluid MCS/AFB negTurbid bloodstained fluidNumerous lymphocytes, histiocytes and blood.noneLarge right main pulmonary artery thrombus. Multiple left sided pulmonary emboli. Bilateral pleural effusions with consolidaton/atelectasis. 2 small round pulmonary foci and a band of consolidation in the right upper lobe. Wedge-shaped consolidation in the middle and right lower lobes.Pleural effusions resolved after 1 year (cyclophosphamide and weaning prednisolone)\*These were the key factors used by the mutldisciplinary team in securing a diagnosis

Eight (73%) were commenced on prednisolone acutely (vasculitis, SLE, drug-related lupus, 1 patient with rheumatoid arthritis, Behcet's, 2 patients with Adult Still's disease, 1 patient with IgG4-related disease). Of these 8, one patient with rheumatoid arthritis received IV methylprednisolone beforehand, one patient with IgG4-related disease was weaned off prednisolone to methothrexate, two patients with Adult Still's disease were on colchicine as well, and one patient with Behcet's was on cyclophosphamide as well. 7 (64%) were managed as outpatients; 4 required admission. The median time from pleural review to diagnosis was 53 days.

Discussion {#Sec8}
==========

In the work up for interstitial lung disease (ILD), assessment by a rheumatologist is recommended in suspected CTD \[[@CR9]\]. The input of a rheumatologist is invaluable in providing an expert clinical review, then directing and interpreting autoimmune testing. Our centre has found this to be the case -- in managing CTD-related pleural effusions. The lung inflammation service was set up to assist the critical critical care team in managing severe respiratory failure; they now work closely with the pleural service as well. To our knowledge, this is the first published evaluation of a collborative approach for inflammatory pleural disease. Case reports of CTD-related serositis do not describe a similarly coordinated approach \[[@CR10]--[@CR12]\]. Our results suggest that the value of pleural fluid and tissue analysis is to exclude common conditions such as malignancy and infection, while a multidisciplinary approach integrating all available diagnostic information is needed for complex cases such as CTD related pleuritis.

In this service evaluation, the multidisciplinary approach to CTD-related pleural effusions has demonstrated efficiency in achieving a diagnosis in a median of 53 days from the first review by the pleural team. Pleural procedures were streamlined, with 73% of diagnoses being achieved by local anaesthetic interventions. 64% of cases were managed in the outpatient setting. Published data describe the outcomes of pleural service outcomes as a whole \[[@CR13], [@CR14]\]. This is the first study to focus on the management of CTD-related pleural effusions.

The study was limited by the small number of cases, due to the rareity of CTD-related pleural effusions. A multi-centre collaboration to establish a larger database would facilitate advancement in best managing this complex patient cohort.

Conclusions {#Sec9}
===========

Diagnosis can be challenging in patients presenting with pleural disease as the first manifestation of a CTD. We recommend a multidisciplinary approach in management.

CTD

:   connective disease disease

ILD

:   interstitial lung disease

SLE

:   systemic lupus erythematosus

VATS

:   video-assisted thoracoscopic surgery
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